REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNXGet Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $35.45.

A number of research analysts recently weighed in on the stock. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Raymond James restated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. Finally, Barclays lowered their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th.

Read Our Latest Stock Analysis on RGNX

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now directly owns 11,286 shares in the company, valued at $114,101.46. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Argeris N. Karabelas sold 10,100 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $13.51, for a total transaction of $136,451.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at $152,473.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,200 shares of company stock worth $354,651. 13.13% of the stock is owned by company insiders.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently made changes to their positions in RGNX. Redmile Group LLC lifted its holdings in REGENXBIO by 21.0% during the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company’s stock worth $95,901,000 after purchasing an additional 790,866 shares during the last quarter. Assenagon Asset Management S.A. increased its position in REGENXBIO by 258.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock worth $9,552,000 after buying an additional 588,773 shares during the period. Vanguard Group Inc. increased its position in REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after buying an additional 436,043 shares during the period. Artal Group S.A. acquired a new stake in shares of REGENXBIO during the first quarter worth $5,268,000. Finally, Integral Health Asset Management LLC boosted its position in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after acquiring an additional 190,000 shares during the period. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $9.06 on Wednesday. The company has a market cap of $446.26 million, a PE ratio of -1.54 and a beta of 1.21. The stock has a 50-day simple moving average of $10.98 and a 200 day simple moving average of $12.84. REGENXBIO has a 52-week low of $8.90 and a 52-week high of $28.80.

REGENXBIO (NASDAQ:RGNXGet Free Report) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $22.97 million. During the same period last year, the business earned ($1.66) EPS. The business’s quarterly revenue was up 11.6% on a year-over-year basis. On average, research analysts predict that REGENXBIO will post -4.66 earnings per share for the current fiscal year.

About REGENXBIO

(Get Free Report

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Read More

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.